OncoMatch/Clinical Trials/NCT06050707
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Is NCT06050707 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for anal squamous cell carcinoma.
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage T1-4, N0-1 (UICC/AJCC 8th Ed)
Clinical stage T1-4 N0-1 M0 (the Union for International Cancer Control (UICC) / the American Joint Committee on Cancer (AJCC) 8th Ed)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Previous chemotherapy...for anal cancer.
Cannot have received: radiation therapy
Previous...RT...for anal cancer.
Cannot have received: curative-intent surgical treatment (i.e. APR)
Previous...curative-intent surgical treatment (i.e. APR) for anal cancer.
Cannot have received: radiation therapy
Any previous RT to the abdomino-pelvic region that would result in overlap of RT volume for the current study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Allegheny Health Network · Pittsburgh, Pennsylvania
- Medical College of Wisconsin Cancer Center · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify